Study Shows Positive Results for mRNA-Based Combination Influenza and COVID-19 Vaccine
A Phase I/II study evaluating the safety, tolerability and immunogenicity of Pfizer and BioNTech’s mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age show positive topline results.
IVIG Reduces Infection Risk During Anti-BCMA Treatment for MM
Data suggests the bispecific BCMA-targeted antibody teclistamab may lead to grade 3 to 5 infections in as many as 44.8 percent of multiple myeloma patients, and hypogammaglobulinemia was noted in nearly 75 percent of patients.
Intranasal COVID-19 Vaccine Shows High Seroresponse
A Phase I randomized, double-blind, placebo-controlled dose-escalation study in healthy adults, called CDX-CoV-001, has found Codagenix’s intranasal COVID-19 vaccine candidate, CoviLiv, showed the vaccine had a high seroresponse rate and induced mucosal immunity in volunteers not previously vaccinated or infected.
Moderna’s Influenza-COVID-19 Vaccine Demonstrates Immunogenecity
Results from Moderna’s Phase I/II clinical trial that evaluated the safety and immunogenicity of its influenza-COVID-19 vaccine, mRNA 1083, showed immunogenicity against all four influenza strains compared to a standard dose of the influenza vaccine, Fluarix, in adults 50 to 64 years of age and against an enhanced influenza vaccine, Fluzone HD, in adults 65 to 79 years of age.
Inverse Vaccine May Reverse Autoimmune Diseases
Researchers from the Pritzker School of Molecular Engineering at the University of Chicago have developed a new type of vaccine called an “inverse vaccine that completely reversed autoimmune diseases without fully shutting down the rest of the immune system.
Study Shows Not All IVIG Products Are Effective in Treating Alzheimer’s
A recent study has found that one specific intravenous immune globulin (IVIG) product was more effective than others in counteracting the cognitive deficits, ameliorating b-amyloid (Ab) deposits and tau phosphorylation among mice with Alzheimer disease (AD)
Scientists Identify Driver of Inflammatory Bowel Disease
Researchers at UT Southwestern Medical Center have discovered an intracellular mechanism that converts protective intestinal cells into disease-driving pathogenic cells, a finding that could lead to improved treatments for patients with inflammatory bowel disease.
Personalized Digital Care Program Improves Outcomes in Long COVID and Autoimmune Disease
According to data, patients with autoimmune diseases or long COVID who used a personalized digital care program (DCP) developed by Mymee alongside other nonpharmacologic strategies were more likely to achieve better health-related quality of life scores.
Researchers Discover How Melanoma Evades the Immune System
Researchers from Sanford Burnham have found that a protein known to be active in immune cells is also active inside melanoma cells, helping promote tumor growth, suggesting that targeting this protein with new drugs may deliver a powerful double hit to melanoma tumors.
FcRn Antagonists: A Panoply of Autoimmune Disorders Now in the Development Pipeline
Specifically designed to blockade the physiologic IgG recycling function of endothelial cell neonatal crystallizable fragment receptor (FcRn), FcRn antagonists represent a new class of monoclonal antibody-based drugs that have been shown to mediate a sharp, dose-dependent reduction in circulation IgG levels.